Biocartis raises €30m for DNA diagnostics

The round was led by Aescap Venture, and including two new investors: the Debiopharm Group and Johnson & Johnson Development Corporation. The round also consisted of previous investors Biovest, Advent Venture Partnets, several Biocartis employees and Benaruca, the family investment vehicle of Biocartis’ co-founder Rudi Pauwels.

Biocartis recently acquired technology from Philips for automated DNA and RNA molecular diagnostic testing. Together, with its new capital, Biocartis hopes to advance its diagnostics platform for low to highly multiplexed detection, quantification, and amplification of molecular-based biomarkers, including nucleic acids, proteins, and small molecules.

Biocartis’ director and CEO Rudi Pauwels said, “This successful financing, within weeks after closing the acquisition of the Philips technology, is yet another important step in our plans to bring a novel and cost-effective diagnostic solution to the healthcare community.”

Lead investor Aescap Venture exclusively backs European medical companies.

Copyright © 2010 AltAssets